Chris Varma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioPharma

- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRASG12C- FMC-376 has the potential to transform patient outcomes with

Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) insider Percy H. Carter sold 2,307 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $52.06, for a total value of $120,102.42. Following the sale, the insider now owns 38,117 shares in the company, valued at […]

SVB Securities cut shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a market perform rating to an underperform rating in a research report released on Monday, The Fly reports. They currently have $43.00 price objective on the biotechnology company’s stock, down from their prior price objective of $48.00. BPMC has been the subject of […]

SVB Securities lowered shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a market perform rating to an underperform rating in a research report report published on Monday morning, The Fly reports. SVB Securities currently has $43.00 price objective on the biotechnology company’s stock, down from their previous price objective of $48.00. Other analysts have […]